Nature Aging,
Год журнала:
2023,
Номер
3(1), С. 82 - 92
Опубликована: Янв. 12, 2023
Abstract
Whether
age-associated
defects
in
T
cells
impact
the
immunogenicity
and
reactogenicity
of
mRNA
vaccines
remains
unclear.
Using
a
vaccinated
cohort
(
n
=
216),
we
demonstrated
that
older
adults
(aged
≥65
years)
had
fewer
vaccine-induced
spike-specific
CD4
+
including
CXCR3
circulating
follicular
helper
H
1
subset
after
first
dose,
which
correlated
with
their
lower
peak
IgG
levels
systemic
adverse
effects
second
compared
younger
adults.
Moreover,
expressed
higher
programmed
cell
death
protein
1,
negative
regulator
activation,
was
associated
low
CD8
responses.
Thus,
an
inefficient
response
dose
may
reduce
production
cytokines,
even
thereby
lowering
humoral
cellular
immunity
reducing
reactogenicity.
Therefore,
enhancing
following
is
key
to
improving
vaccine
efficacy
Science Translational Medicine,
Год журнала:
2022,
Номер
14(634)
Опубликована: Янв. 14, 2022
Multiple
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
variants
that
have
mutations
associated
with
increased
transmission
and
antibody
escape
arisen
over
the
course
of
current
pandemic.
Although
vaccines
largely
been
effective
against
past
variants,
number
found
on
Omicron
(B.1.1.529)
spike
protein
appear
to
diminish
protection
conferred
by
preexisting
immunity.
Using
vesicular
stomatitis
virus
(VSV)
pseudoparticles
expressing
several
SARS-CoV-2
we
evaluated
magnitude
breadth
neutralizing
response
time
in
individuals
after
infection
mRNA-vaccinated
individuals.
We
observed
boosting
increases
wild-type
(D614),
Beta,
Delta,
variants;
however,
variant
was
most
resistant
neutralization.
further
vaccinated
healthy
adults
had
robust
broad
responses,
whereas
responses
may
reduced
pregnant
women,
underscoring
importance
learning
how
maximize
mRNA
vaccine
populations.
Findings
from
this
study
show
substantial
heterogeneity
vaccination
support
addition
more
conserved
viral
antigens
existing
vaccines.
Viruses,
Год журнала:
2022,
Номер
14(5), С. 961 - 961
Опубликована: Май 4, 2022
The
coronavirus
disease
2019
(COVID-19)
pandemic
is
caused
by
the
severe
acute
respiratory
syndrome
2
(SARS-CoV-2),
a
recently
emerged
human
coronavirus.
COVID-19
vaccines
have
proven
to
be
successful
in
protecting
vaccinated
from
infection,
reducing
severity
of
disease,
and
deterring
transmission
infection.
However,
vaccination
faces
many
challenges,
such
as
decline
vaccine-induced
immunity
over
time,
decrease
potency
against
some
SARS-CoV-2
variants
including
Omicron
variant,
resulting
breakthrough
infections.
challenges
that
facing
highlight
importance
discovery
antivirals
serve
another
means
tackle
pandemic.
To
date,
neutralizing
antibodies
block
viral
entry
targeting
spike
protein
make
up
largest
class
has
received
US
FDA
emergency
use
authorization
(EUA)
for
treatment.
In
addition
protein,
other
key
targets
direct-acting
include
enzymes
are
essential
replication,
RNA-dependent
RNA
polymerase
proteases,
judged
approval
remdesivir,
EUA
Paxlovid
(nirmatrelvir
+
ritonavir)
treating
This
review
presents
an
overview
current
status
future
direction
antiviral
drug
infections,
covering
important
non-structural
(nsp)
3
papain-like
protease,
nsp5
main
nsp12/nsp7/nsp8
complex.
Communications Biology,
Год журнала:
2023,
Номер
6(1)
Опубликована: Фев. 17, 2023
Abstract
Herein,
we
studied
the
impact
of
empty
LNP
(eLNP),
component
mRNA-based
vaccine,
on
anti-viral
pathways
and
immune
function
cells
from
young
aged
individuals.
eLNP
induced
maturation
monocyte
derived
dendritic
(MDDCs).
We
further
show
that
upregulated
CD40
cytokine
production
in
multiple
DC
subsets
monocytes.
This
coincided
with
phosphorylation
TANK
binding
kinase
1
(pTBK1)
interferon
response
factor
7
(pIRF7).
In
to
eLNP,
healthy
older
adults
(>65
yrs)
have
decreased
expression,
IFN-γ
output
compared
(<65
yrs).
Additionally,
a
dysregulated
signaling
stimulation,
measured
by
defect
type
I
IFN
production,
phagocytosis.
Overall,
our
data
eliciting
innate
is
impaired
resulting
lower
responses
SARS-CoV-2
vaccines.
Experimental & Molecular Medicine,
Год журнала:
2023,
Номер
55(7), С. 1305 - 1313
Опубликована: Июль 10, 2023
Since
the
discovery
of
messenger
RNA
(mRNA),
there
have
been
tremendous
efforts
to
wield
them
in
development
therapeutics
and
vaccines.
During
COVID-19
pandemic,
two
mRNA
vaccines
were
developed
approved
record-breaking
time,
revolutionizing
vaccine
landscape.
Although
first-generation
demonstrated
over
90%
efficacy,
alongside
strong
immunogenicity
humoral
cell-mediated
immune
responses,
their
durability
has
lagged
compared
long-lived
vaccines,
such
as
yellow
fever
vaccine.
worldwide
vaccination
campaigns
saved
lives
estimated
tens
millions,
side
effects,
ranging
from
mild
reactogenicity
rare
severe
diseases,
reported.
This
review
provides
an
overview
mechanistic
insights
into
responses
adverse
effects
documented
primarily
for
Furthermore,
we
discuss
perspectives
this
promising
platform
challenges
balancing
effects.
Journal of Clinical Investigation,
Год журнала:
2023,
Номер
133(10)
Опубликована: Март 23, 2023
BackgroundMaintaining
durable
immunity
following
vaccination
represents
a
major
challenge,
but
whether
mRNA
booster
improves
durability
is
unknown.MethodsWe
measured
antibody
responses
in
55
healthy
adults,
who
received
dose
of
the
Pfizer-BioNTech
or
Moderna
vaccine
against
SARS-CoV-2
and
calculated
half-life
titers.
We
also
memory
B
T
cell
subset
28
participants.
In
13
volunteers
second
vaccine,
we
serum
titers
responses.ResultsThe
(third
immunization)
at
6
to
10
months
increased
serum-neutralizing
(nAb)
76
days
from
56
66
after
primary
2-dose
vaccination.
A
(fourth
year
further
88
days.
However,
despite
this
modestly
improved
nAb
ancestral
(WA.1)
strain,
there
was
loss
neutralization
capacity
Omicron
subvariants
BA.2.75.2,
BQ.1.1,
XBB.1.5
(48-,
71-,
66-fold
drop
titers,
respectively,
relative
WA.1
strain).
Although
only
45%
65%
participants
demonstrated
detectable
titer
newer
variants
dose),
response
declined
below
detection
limit
almost
all
individuals
by
months.
contrast,
induced
antigen-specific
cells
that
persisted
for
least
months.ConclusionThe
marginally
immunizations
with
vaccines.
Abstract
Ferroptosis
is
an
iron‐dependent
cell
death
that
has
been
found
to
aggravate
the
progression
of
osteoarthritis
(OA)
and
gut
microbiota‐
OA
axis
refers
bidirectional
information
network
between
microbiota
OA,
which
may
provide
a
new
way
protect
OA.
However,
role
microbiota‐derived
metabolites
in
ferroptosis‐relative
remains
unclear.
The
objective
this
study
was
analyze
protective
effect
its
metabolite
capsiate
(CAT)
on
vivo
vitro
experiments.
From
June
2021
February
2022,
78
patients
were
evaluated
retrospectively
divided
into
two
groups:
health
group
(
n
=
39)
40).
Iron
oxidative
stress
indicators
determined
peripheral
blood
samples.
And
then
experiments,
surgically
destabilized
medial
meniscus
(DMM)
mice
model
established
treated
with
CAT
or
Ferric
Inhibitor‐1
(Fer‐1).
Solute
Carrier
Family
2
Member
1
(SLC2A1)
short
hairpin
RNA
(shRNA)
utilized
inhibit
SLC2A1
expression.
Serum
iron
increased
significantly
but
total
binding
capacity
decreased
than
healthy
people
p
<
0.0001).
least
absolute
shrinkage
selection
operator
clinical
prediction
suggested
serum
iron,
capacity,
transferrin,
superoxide
dismutase
all
independent
predictors
0.001).
Bioinformatics
results
SLC2A1,
Metastasis‐Associated
Lung
Adenocarcinoma
Transcript
(MALAT1),
HIF‐1α
(Hypoxia
Inducible
Factor
Alpha)‐related
signaling
pathways
play
important
homeostasis
In
addition,
16s
sequencing
untargeted
metabolomics
used
find
negatively
correlated
Osteoarthritis
Research
Society
International
(OARSI)
scores
for
chondrogenic
degeneration
0.0017).
Moreover,
reduced
ferroptosis‐dependent
vitro.
against
could
be
eliminated
by
silencing
SLC2A1.
upregulated
levels
DMM
group.
HIF‐1α,
MALAT1,
apoptosis
after
knockout
chondrocyte
cells
Finally,
downregulation
expression
Adeno‐associated
Virus
(AAV)
‐SLC2A1
shRNA
improves
vivo.
Our
findings
indicated
inhibited
HIF‐1a
activating
Immunity,
Год журнала:
2023,
Номер
56(4), С. 864 - 878.e4
Опубликована: Март 16, 2023
T
cells
are
a
critical
component
of
the
response
to
SARS-CoV-2,
but
their
kinetics
after
infection
and
vaccination
insufficiently
understood.
Using
"spheromer"
peptide-MHC
multimer
reagents,
we
analyzed
healthy
subjects
receiving
two
doses
Pfizer/BioNTech
BNT162b2
vaccine.
Vaccination
resulted
in
robust
spike-specific
cell
responses
for
dominant
CD4